Co-administration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 2, 2009, Pages 316-319

  Wakeham, Katie ^a,b   Parkes Ratanshi, Rosalind ^a,b   Watson, Victoria ^c,d   Ggayi, Abu Baker ^a   Khoo, Saye ^c   Lalloo, David G ^b  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Antiretroviral therapy; Drug interactions; Pharmacokinetics; Uganda

Indexed keywords

FLUCONAZOLE; NEVIRAPINE; PLACEBO;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYPTOCOCCOSIS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ERUPTION; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PRIMARY PREVENTION; SIDE EFFECT; STEVENS JOHNSON SYNDROME; UGANDA;

EID: 77950203397     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp451     Document Type: Article

References (11)

1. Parkes-Ratanshi R, Kamali A, Wakeham K et al. Successful primary prevention of cryptococcal disease using fluconazole prophylaxis in HIV-infected Ugandan adults. In: Abstracts of the Sixteenth Conference on Retroviruses and Opportunistic Infections, Montreal, 2009. Abstract P-32. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
2. Bruggemann RJ, Alffenaar JW, Blijlevens NM et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009; 48: 1441-58.
3. Wen B, Chen Y, Fitch WL. Metabolic activation of nevirapine in human liver microsomes: dehydrogenation and inactivation of cytochrome P450 3A4. Drug Metab Dispos 2009; 37: 1557-62.
4. Manosuthi W, Sungkanuparph S, Tansuphaswadikul S et al. Incidence and risk factors of nevirapine-associated severe hepatitis among HIV-infected patients with CD4 cell counts less than 250 cells/microL. J Med Assoc Thai 2008; 91: 159-65.
5. World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach, 2006 Revision. http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf (18 November 2009, date last accessed).
6. Geel J, Pitt J, Orrell CJ et al. The effect of fluconazole on nevirapine. In: Abstracts of the Fifteenth International Conference on AIDS, Bangkok, Thailand, 2004. Abstract WeOrB1239.
7. Kikaire B, Khoo S, Walker AS et al. Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy. AIDS 2007; 21: 733-7.
8. Jaruratanasirikul S, Sriwiriyajan S. Pharmacokinetic study of the interaction between itraconazole and nevirapine. Eur J Clin Pharmacol 2007; 63: 451-6.
9. Manosuthi W, Athichathanabadi C, Uttayamakul S et al. Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole. BMC Infect Dis 2007; 7: 14.
10. Phanuphak N, Apornpong T, Teeratakulpisarn S et al. Nevirapineassociated toxicity in HIV-infected Thai men and women, including pregnant women. HIV Med 2007; 8: 357-66.
11. Almond LM, Boffito M, Hoggard PG et al. The relationship between nevirapine plasma concentrations and abnormal liver function tests. AIDS Res Hum Retroviruses 2004; 20: 716-22.